

**P&T Motion History**  
**Long-Acting Insulins for Type 1 and Type 2 Diabetes**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
insulin detemir <b>insulin degludec</b> <b>insulin degludec/</b> <b>insulin aspart</b> insulin glargine	<p>After considering the evidence of safety, efficacy and special populations for the treatment of type 1 and type 2 diabetes, I move that insulin detemir, insulin glargine, insulin degludec, and insulin degludec/ insulin aspart combination are safe and efficacious for the treatment of their approved indications. Single agent long-acting insulins can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Figueroa            2<sup>nd</sup>: Sanderson</p>	December 20, 2017	NA	No	Passed unanimous
insulin detemir insulin glargine	<p>After considering the evidence of safety, efficacy and special populations for the treatment of type 1 and type 2 diabetes, I move that insulin detemir and insulin glargine are safe and efficacious for the treatment of their approved indications. Long-acting insulins can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Wisner            2<sup>nd</sup>: Johnson</p>	December 21, 2016	Yes Harvey Sanderson	Yes Klingel Bowman	Passed unanimous

**Bold** =new this review